Basilea Pharmaceutica AG (BPMUF)
OTCMKTS · Delayed Price · Currency is USD
71.00
-0.60 (-0.84%)
At close: Jan 30, 2026
Basilea Pharmaceutica AG Employees
Basilea Pharmaceutica AG had 180 employees as of June 30, 2025. The number of employees increased by 16 or 9.76% since the number was reported on December 31, 2024.
Employees
180
Change
16
Growth
9.76%
Revenue / Employee
$1,650,083
Profits / Employee
$507,564
Market Cap
922.35M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 180 | 16 | 9.76% |
| Dec 31, 2024 | 164 | 17 | 11.56% |
| Dec 31, 2023 | 147 | 6 | 4.26% |
| Dec 31, 2022 | 141 | -13 | -8.44% |
| Dec 31, 2021 | 154 | -3 | -1.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Basilea Pharmaceutica AG News
- 3 days ago - Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea - GlobeNewsWire
- 4 weeks ago - Basilea Pharmaceutica Partners With INCATE To Advance Antibacterial And Antifungal Innovation - Nasdaq
- 5 weeks ago - Basilea provides portfolio update and outlook - GlobeNewsWire
- 5 weeks ago - Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections - PRNewsWire
- 2 months ago - Basilea partners with Phare Bio to deploy generative AI for antibiotic discovery - Seeking Alpha
- 2 months ago - Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic - GlobeNewsWire
- 2 months ago - Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI - Business Wire
- 3 months ago - Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea - GlobeNewsWire